Review Article: GLP-1 Receptor Agonists and Glucagon/GIP/GLP-1 Receptor Dual or Triple Agonists-Mechanism of Action and Emerging Therapeutic Landscape in MASLD.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Review Article: GLP-1 Receptor Agonists and Glucagon/GIP/GLP-1 Receptor Dual or Triple Agonists-Mechanism of Action and Emerging Therapeutic Landscape in MASLD.
- Published In:
- Alimentary pharmacology & therapeutics, 61(12), 1872-1888 (2025)
- Database ID:
- RPEP-14439
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-14439APA
Zafer, Maryam; Tavaglione, Federica; Romero-Gómez, Manuel; Loomba, Rohit. (2025). Review Article: GLP-1 Receptor Agonists and Glucagon/GIP/GLP-1 Receptor Dual or Triple Agonists-Mechanism of Action and Emerging Therapeutic Landscape in MASLD.. Alimentary pharmacology & therapeutics, 61(12), 1872-1888. https://doi.org/10.1111/apt.70196
MLA
Zafer, Maryam, et al. "Review Article: GLP-1 Receptor Agonists and Glucagon/GIP/GLP-1 Receptor Dual or Triple Agonists-Mechanism of Action and Emerging Therapeutic Landscape in MASLD.." Alimentary pharmacology & therapeutics, 2025. https://doi.org/10.1111/apt.70196
RethinkPeptides
RethinkPeptides Research Database. "Review Article: GLP-1 Receptor Agonists and Glucagon/GIP/GLP..." RPEP-14439. Retrieved from https://rethinkpeptides.com/research/zafer-2025-review-article-glp1-receptor
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.